| abstract |
Lipophosphonoxins of formula I, wherein R is C8-C22, more preferably C10-C18 and preferably C12-C16 alkyl or hexadecyloxypropyl, tetradecyloxypropyl, tetradecyloxyethyl or hexadecyloxyethyl, R is uracil, thymine or cytosine, R is selected from the group consisting of compounds of formulas II to R, wherein R is H, CHOH or CHNH, R is H, OH or NH, R is H, OH or NH, R is H, CHOH or CHNH, wherein at least one of the groups Ra Rm must be NH or one of the groups Ra Rm must be CHNH-Rje H, CHOH or CHNH, R is H, OH or NH, R is H, OH or NH, R is H, OH or NH, R is H, CHOH or CHNH, at least one of the groups R, Ra R must be NH or one of the groups Ra R must be CHNH. R is NH or NH-CH (NH) NH, R is NH or NH-CH (NH) NH, R is NH or NH-CH (NH) NH, R is NH or NH-CH (NH) NH. Further described are diastereomers and mixtures of diastereomers of the compounds of formula I as well as the corresponding pharmaceutically acceptable salts and hydrates. All of the compounds of formula I are useful as antibacterial agents or active ingredients in disinfectants and / or selective culture media. |